Tian Zhang

Positions:

Assistant Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2009

Harvard Medical School

M.H.S. 2019

Duke University School of Medicine

Internal Medicine Residency, Medicine

Duke University School of Medicine

Fellowship in Hematology-Oncology, Medicine

Duke University School of Medicine

Grants:

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Administered By
Medicine, Medical Oncology
Awarded By
National Institutes of Health
Role
Significant Contributor
Start Date
End Date

CTC-Immune Checkpoints

Administered By
Duke Cancer Institute
Role
Co-Principal Investigator
Start Date
End Date

Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer

Administered By
Medicine, Medical Oncology
Awarded By
V Foundation for Cancer Research
Role
Principal Investigator
Start Date
End Date

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

A Salvage Trial of AR Inhibition with ADT and Apalutamide with Docetaxel followed by Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy (¿STARTAR¿)

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).

Authors
Labriola, M; Zhu, J; Gupta, R; McCall, S; Jackson, J; White, JR; Weingartner, E; Kong, E; Simone, P; Papp, E; Gerding, K; Simmons, J; George, DJ; Zhang, T
MLA Citation
Labriola, Matthew, et al. “Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC)..” Journal of Clinical Oncology, vol. 37, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. e16079–e16079. Crossref, doi:10.1200/jco.2019.37.15_suppl.e16079.
URI
https://scholars.duke.edu/individual/pub1415115
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
e16079
End Page
e16079
DOI
10.1200/jco.2019.37.15_suppl.e16079

A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).

Authors
Zhang, T; Koontz, BF; Tagawa, ST; Nagar, H; Bitting, RL; Frizzell, B; Rasmussen, J; Wilder, R; Anand, M; Winters, C; Riggan, C; Lee, A; Healy, P; Wu, Y; McNamara, MA; Harrison, MR; George, DJ; Armstrong, AJ
MLA Citation
Zhang, Tian, et al. “A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR)..” Journal of Clinical Oncology, vol. 37, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. TPS5097–TPS5097. Crossref, doi:10.1200/jco.2019.37.15_suppl.tps5097.
URI
https://scholars.duke.edu/individual/pub1415222
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
TPS5097
End Page
TPS5097
DOI
10.1200/jco.2019.37.15_suppl.tps5097

Immune checkpoint inhibitor response in tumors with LRP1B variants.

Authors
Zhu, J; Tucker, MD; Kao, C; Labriola, M; Cheris, S; Datto, MB; Wu, Y; Healy, P; Gupta, S; Kirtane, K; Gupta, RT; Marin, D; Zhang, T; McNamara, MA; Harrison, MR; George, DJ; Armstrong, AJ
MLA Citation
Zhu, Jason, et al. “Immune checkpoint inhibitor response in tumors with LRP1B variants..” Journal of Clinical Oncology, vol. 37, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. e14291–e14291. Crossref, doi:10.1200/jco.2019.37.15_suppl.e14291.
URI
https://scholars.duke.edu/individual/pub1415278
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
e14291
End Page
e14291
DOI
10.1200/jco.2019.37.15_suppl.e14291

Ki67 proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastases

© 2017 Ivyspring International Publisher. Background: To investigate the relationship between clinical and histopathological characteristics and overall survival of patients with oral mucosal melanoma (OMM) without distal metastasis in order to provide predictive prognostic information of OMM. Methods: Ki67 expression was assessed by immunohistochemistry in 123 patients with OMM without distant metastases. The associations between Ki67 expression and clinical features and overall survival (OS) of patients were statistically analyzed. The Ki67 levels of the primary and recurrent lesions from 14 OMM patients were compared. Results: Univariate analysis showed that tumor type and cervical lymph node (CLN) status, as well as Ki67 expression, were all correlated with survival. Cox proportional hazards regression analysis identified Ki67 expression and CLN status as independent prognostic factors in OMM patients. Further, we found that Ki67 expression was associated with clinical tumor type of OMM. Moreover, with a cut-off point of 20%, patients with lower Ki67 scores showed a survival advantage over those with higher Ki67 scores. Conclusions: Ki67 expression may be a useful pathological predictor of survival of OMM patients without distant metastases.
Authors
Ma, X; Wu, Y; Zhang, T; Song, H; Jv, H; Guo, W; Ren, G
MLA Citation
Ma, X., et al. “Ki67 proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastases.” Journal of Cancer, vol. 8, no. 18, Jan. 2017, pp. 3828–37. Scopus, doi:10.7150/jca.20935.
URI
https://scholars.duke.edu/individual/pub1421337
Source
scopus
Published In
Journal of Cancer
Volume
8
Published Date
Start Page
3828
End Page
3837
DOI
10.7150/jca.20935

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Authors
Zhu, J; Pabla, S; Labriola, M; Gupta, RT; McCall, S; George, DJ; Dressman, D; Glenn, S; George, S; Morrison, C; Zhang, T
MLA Citation
Zhu, Jason, et al. “Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC)..” Journal of Clinical Oncology, vol. 37, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. 2595–2595. Crossref, doi:10.1200/jco.2019.37.15_suppl.2595.
URI
https://scholars.duke.edu/individual/pub1415279
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
2595
End Page
2595
DOI
10.1200/jco.2019.37.15_suppl.2595